Fig. 3.

Toca 511 and 5-FC treatment reduces Th2 and Th17 cells in the tumor 6 and 9 days after 5-FC treatment initiation while enhancing expression of TNFα at day 6 and TNFα and IFNγ at day 9. (A) Intracellular staining for IL-4 and IL-17 was conducted and expressed as a percentage of CD4+ T cells in the tumor 6 days after initiation of treatment with 5-FC. (B) Six days after 5-FC treatment initiation, intracellular staining for TNFα was conducted and expressed as a percentage of CD3−, or non–T cells in the tumor. (C) Intracellular staining for IL-4 and IL-17 was conducted and expressed as a percentage of CD4+ T cells in the tumor 9 days after initiation of treatment with 5-FC. (D) Nine days after 5-FC treatment initiation, intracellular staining for TNFα and IFNγ was conducted and expressed as a percentage of CD3−, or non–T cells in the tumor. (E) Intracellular staining for IFNγ was conducted and expressed as a percentage of CD8+ T cells in the tumor 9 days after initiation of treatment with 5-FC. These data, n = 5, were repeated with similar results in at least one additional experiment.